2025
Impact of Abatacept Inclusive Graft Versus Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy
Shah N, Ngwube A, Suresh T, Sowa A, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier G, Dalal J, Grimley M, Jacobsohn D, Kamani N, Krajewski J, Krishnamurti L, Saini S, Skiles J, Shenoy S. Impact of Abatacept Inclusive Graft Versus Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy. Transplantation And Cellular Therapy 2025 PMID: 40543708, DOI: 10.1016/j.jtct.2025.06.015.Peer-Reviewed Original ResearchGraft-versus-host diseaseChronic graft-versus-host diseaseHematopoietic cell transplantationGraft-versus-host disease prophylaxisGVHD prophylaxisAbatacept groupCell transplantationIncidence of posterior reversible encephalopathy syndromeSeverity of graft-versus-host diseasePresence of graft-versus-host diseasePosterior reversible encephalopathy syndromeAllogeneic hematopoietic cell transplantationSibling donor hematopoietic cell transplantationDonor hematopoietic cell transplantationDonor-derived hematopoiesisImmune reconstitution patternsReduced intensity conditioningEvent-free survivalGraft-versus-hostHost disease prophylaxisReversible encephalopathy syndromeSystemic immune suppressionStem cell transplantationPrimary graft rejectionPediatric stem cell transplantationComparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease
Prior D, Liang J, Deng Y, Shah N, Flagg A, Krishnamurti L. Comparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2025 PMID: 40379050, DOI: 10.1016/j.jtct.2025.05.004.Peer-Reviewed Original ResearchGraft-versus-host diseaseHematopoietic cell transplantationHLA-matched related donorSickle cell diseaseConditioning regimen intensityAnti-thymocyte globulinEFS ratesConditioning regimensRegimen intensityCell transplantationRate of chronic graft-versus-host diseaseRelated donorsChronic graft-versus-host diseaseHematopoietic cell transplantation regimensNon-myeloablative conditioning regimensAllogeneic hematopoietic cell transplantationCell diseaseComparison of regimensMyeloablative conditioning regimensNon-myeloablative conditioningNon-myeloablative regimensSickle cell disease patientsEvent-free survivalGraft-versus-hostAnti-thymocyteDonor, Recipient, and Parent Characteristics Associated with Poor Pediatric Sibling Hematopoietic Stem Cell Donor Pre-Donation Health-Related Quality-of-Life; Early Results of the Donorkids QL Study
Switzer G, Bruce J, Shaw B, Kuniyil V, Varni J, Butler B, Erickson C, Mussetter A, Aguayo-Hiraldo P, Anderson E, Aquino V, Boone K, Chewning J, Dahlberg A, Dvorak C, Haight A, Hoag J, Hudspeth M, Jacobsohn D, Kasow K, Kitko C, Miller H, Olson T, Pawlowska A, Prasad V, Quigg T, Scaradavou A, Shah N, Shenoy S, Silva J, Terwilliger N, Wiener L, Yanik G, Yu L, Pulsipher M. Donor, Recipient, and Parent Characteristics Associated with Poor Pediatric Sibling Hematopoietic Stem Cell Donor Pre-Donation Health-Related Quality-of-Life; Early Results of the Donorkids QL Study. Transplantation And Cellular Therapy 2025, 31: s95-s96. DOI: 10.1016/j.jtct.2025.01.151.Peer-Reviewed Original ResearchHealth-related quality-of-lifeQuality-of-lifePoorer health-related quality-of-lifeFamily unitFamily cohesionPredictors of HRQoL.Aged 5Low parental education levelSelf-reported depressionParental demographic characteristicsParental education levelDonation processParental HRQoLPsychosocial scoresPartnership statusLow family cohesionQL studiesFamily characteristicsPsychosocial effectsHRQoLEmployment statusEducation levelHRQoL.Pre-donationInterview dataNew Beginnings: Implementing a Pediatric Hemopoietic Stem Cell and Cellular Therapy Program
Fastenau S, Dillard S, McEntee N, Centofanti D, Ramos R, Shah N. New Beginnings: Implementing a Pediatric Hemopoietic Stem Cell and Cellular Therapy Program. Transplantation And Cellular Therapy 2025, 31: s475. DOI: 10.1016/j.jtct.2025.01.745.Peer-Reviewed Original ResearchTherapy programRegistered nursesNursing care needsFull-day sessionsPost-testEvidence-based advancesTransplantation processNursing interventionsNursing careNursing staffCare needsStem cell transplantation processesEducation sessionsNursesStaff trainingEducation programsIntensive care unitTeam membersEducational conferencesSkill componentsStaffEducation staffMaximum attendanceCare unitIdentifying opportunities
2024
Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease
Krishnamurti L, Liang J, He Z, Deng Y, Nallagatla V, Hamidi R, Flagg A, Shah N. Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease. Blood Advances 2024, 8: 1908-1919. PMID: 38324722, PMCID: PMC11021890, DOI: 10.1182/bloodadvances.2023010749.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseVaso-occlusive episodesPainful crisesCell transplantationPost-HCTGraft failureBefore HCTEvent-free survivalOverall survivalPain syndromePatient agePatient-centered outcomesAlternative donorsIncreased riskCell diseaseRisk factorsNatural historyPatientsLogistic regressionPainTransplantationSurvivalAgeAGVHDImpact of CMV Reactivation on Clinical Outcomes Post Allogeneic Stem Cell Transplant in Patients with Sickle Cell Disease
Rahim M, Ngwube A, Shenkar R, Rohaum H, Rao A, Stanek J, Shah N, Rangarajan H. Impact of CMV Reactivation on Clinical Outcomes Post Allogeneic Stem Cell Transplant in Patients with Sickle Cell Disease. Transplantation And Cellular Therapy 2024, 30: s302. DOI: 10.1016/j.jtct.2023.12.413.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationImpact of CMV reactivationReduced intensity conditioningSickle cell disease patientsAllogeneic hematopoietic stem cell transplantationSickle cell diseaseStem cell transplantationCMV reactivationMixed chimerismCell transplantationGraft failurePost-allogeneic hematopoietic stem cell transplantationRecovery of absolute lymphocyte countPost allogeneic stem cell transplantationAbsence of CMV-reactivationAllogeneic stem cell transplantationRabbit anti-thymocyte globulinMulti-institutional retrospective studyWhole bloodRisk of graft failureIncidence of GFPre-engraftment periodAnti-thymocyte globulinAbsolute lymphocyte countCompare clinical outcomes
2023
Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders
Ngwube A, Shah N, Schulz G, Krishnamurti L, Shenoy S. Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders. Blood 2023, 142: 4901. DOI: 10.1182/blood-2023-191145.Peer-Reviewed Original ResearchNon-malignant disordersPost-transplant cyclophosphamideSickle cell diseaseGVHD prophylaxisHematopoietic transplantationEvaluable patientsHaploidentical transplantationImmune suppressionBone marrowFirst year post-HCTGrade 1 acute GVHDChronic GVHD riskChronic skin GVHDGVHD-free survivalPost-transplant lymphoproliferationsRadiation-containing regimensYear post-HCTPhase 2 trialReduced intensity conditioningSerious infectious complicationsSystemic immune suppressionT-cell chimerismAllogeneic hematopoietic transplantationPrimary outcome measureStem cell boostOutcomes after RIC and Abatacept-Based Acute and Chronic Gvhd Prophylaxis in Allogeneic Transplantation for Sickle Cell Disease - Can Calcineurin Inhibitor Use be Curtailed?
Shah N, Ngwube A, Jacobsohn D, Shenoy S. Outcomes after RIC and Abatacept-Based Acute and Chronic Gvhd Prophylaxis in Allogeneic Transplantation for Sickle Cell Disease - Can Calcineurin Inhibitor Use be Curtailed? Blood 2023, 142: 2185. DOI: 10.1182/blood-2023-190524.Peer-Reviewed Original ResearchDisease-free survivalSickle cell diseaseSevere sickle cell diseaseUnrelated donor transplantsGVHD prophylaxisAllogeneic transplantationCell diseaseChronic GVHDDonor transplantsMarrow transplantationGrade 2Unrelated donor stem cell transplantationAllogeneic T cell proliferationDonor stem cell transplantationUnrelated donor marrow transplantationCalcineurin inhibitor useHost disease (GVHD) prophylaxisRelated donor transplantsSevere chronic GVHDSuccessful allogeneic transplantationGroup 1 patientsPhase II trialImmune suppression therapyStem cell transplantationHuman leucocyte antigenCongenital Dyserythropoietic Anemia Type II: An Update from the Congenital Dyseryhtropoietic Anemia Registry of North America (CDAR)
Elgammal Y, Risinger M, Husami A, Walden J, Gupta S, Shah N, Boyer J, Abajas Y, Winstead M, Miller D, Vidal-Anaya V, Vlachos A, Lal A, Ritchey A, Lorsbach R, Zhang W, Kalfa T, Niss O. Congenital Dyserythropoietic Anemia Type II: An Update from the Congenital Dyseryhtropoietic Anemia Registry of North America (CDAR). Blood 2023, 142: 1079. DOI: 10.1182/blood-2023-189389.Peer-Reviewed Original ResearchIron overloadIneffective erythropoiesisCongenital dyserythropoietic anemiaBlood transfusionHepatic hemosiderosisHemolytic anemiaIron levelsFrequency of transfusionGDF-15 levelsWhole-genome sequencingSeverity of anemiaAge of diagnosisCDA IINatural history studiesBody iron levelsDeep intronic variantsCDA II patientsCDA type IIIntronic variantsAutosomal recessive diseaseBone marrow erythroblastsBM examinationFerritin ratioGDF-15Anemia severityMediport use as an acceptable standard for CAR T cell infusion
Eylon M, Prabhu S, John S, King M, Bhatt D, Curran K, Erickson C, Karras N, Phillips C, Satwani P, Hermiston M, Southworth E, Baumeister S, Talano J, MacMillan M, Rossoff J, Bonifant C, Myers G, Rouce R, Toner K, Driscoll T, Katsanis E, Salzberg D, Schiff D, De Oliveira S, Capitini C, Pacenta H, Pfeiffer T, Shah N, Huynh V, Skiles J, Fraint E, McNerney K, Quigg T, Krueger J, Ligon J, Fabrizio V, Baggott C, Laetsch T, Schultz L. Mediport use as an acceptable standard for CAR T cell infusion. Frontiers In Immunology 2023, 14: 1239132. PMID: 37965315, PMCID: PMC10642031, DOI: 10.3389/fimmu.2023.1239132.Peer-Reviewed Original ResearchCAR T-cell infusionT-cell infusionCell infusionT-cell therapyCell infiltrationClinical practiceChimeric antigen receptor T-cell therapyCAR T-cell therapyCAR-T cell infiltrationCell therapyCell therapy administrationRetrospective cohort studyCentral venous cathetersT cell infiltrationCurrent clinical practiceStandard clinical practiceB-cell malignanciesT cell deliveryEvaluable patientsVenous optionsCohort studyVenous cathetersTherapy administrationPractice patternsCare recommendationsMixed donor chimerism following stem cell transplantation for sickle cell disease
Shah N, Rangarajan H, Ngwube A, Shenoy S. Mixed donor chimerism following stem cell transplantation for sickle cell disease. Current Opinion In Hematology 2023, 30: 187-193. PMID: 37694765, DOI: 10.1097/moh.0000000000000786.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationDonor/recipient chimerismStem cell transplantationSickle cell diseasePost-HCTRecipient chimerismDonor chimerismCell transplantationCell diseaseDisease controlDonor-derived erythropoiesisHCT conditioning regimensMixed donor chimerismSerial chimerism analysesRecent clinical trialsDonor erythropoiesisConditioning regimensHigh morbidityCurative interventionsClinical trialsSuccessful engraftmentSCD manifestationsMyeloid cellsHb S traitChimerism analysisCan defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?
Shah N, Shenoy S. Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation? The Lancet Haematology 2023, 10: e309-e311. PMID: 37001535, DOI: 10.1016/s2352-3026(23)00065-0.Peer-Reviewed Original Research378 Main Reasons for Performing Hematopoietic Cell Transplantation in Patients with Sickle Cell Disease: Evolution over the Last Three Decades
Flagg A, He Z, Deng Y, Hamidi R, Shah N, Krishnamurti L. 378 Main Reasons for Performing Hematopoietic Cell Transplantation in Patients with Sickle Cell Disease: Evolution over the Last Three Decades. Transplantation And Cellular Therapy 2023, 29: s285-s286. DOI: 10.1016/s2666-6367(23)00447-5.Peer-Reviewed Original Research379 The Impact of Current Conditioning Regimen, T Cell Depletion and Graft Versus Host Disease Prophylaxis on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
Shah N, Flagg A, Hamidi R, Hugo H, Deng Y, Krishnamurti L. 379 The Impact of Current Conditioning Regimen, T Cell Depletion and Graft Versus Host Disease Prophylaxis on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s286-s287. DOI: 10.1016/s2666-6367(23)00448-7.Peer-Reviewed Original Research384 Vaso-Occlusive Pain Requiring Hospitalization or Treatment Is Rare Following Successful Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti L, He Z, Deng Y, Hamidi R, Flagg A, Shah N. 384 Vaso-Occlusive Pain Requiring Hospitalization or Treatment Is Rare Following Successful Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s291. DOI: 10.1016/s2666-6367(23)00453-0.Peer-Reviewed Original Research390 Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell Disease
Flagg A, Hamidi R, He Z, Deng Y, Shah N, Krishnamurti L. 390 Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s296. DOI: 10.1016/s2666-6367(23)00459-1.Peer-Reviewed Original Research392 Avascular Necrosis Following Hematopoietic Cell Transplantation for Sickle Cell Disease
Hamidi R, He Z, Deng Y, Flagg A, Shah N, Krishnamurti L. 392 Avascular Necrosis Following Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s297-s298. DOI: 10.1016/s2666-6367(23)00461-x.Peer-Reviewed Original Research391 Clinical Outcomes and Long-Term Follow-up of Children with Mixed Myeloid Chimerism Following Hematopoietic Cell Transplantation (HCT) for Sickle Cell Disease (SCD)
Guilcher G, Dalal S, Suresh T, Yelamali A, Aljayyousi H, Bhatia M, Haight A, Khandelwal P, Khoury R, Lafay Q, Mandava M, Nickel R, Ngwube A, Rangarajan H, Shah N, Stenger E, Yelamanchili N, Shenoy S. 391 Clinical Outcomes and Long-Term Follow-up of Children with Mixed Myeloid Chimerism Following Hematopoietic Cell Transplantation (HCT) for Sickle Cell Disease (SCD). Transplantation And Cellular Therapy 2023, 29: s296-s297. DOI: 10.1016/s2666-6367(23)00460-8.Peer-Reviewed Original ResearchRole of abatacept in the prevention of graft-versus-host disease: current perspectives
Ngwube A, Rangarajan H, Shah N. Role of abatacept in the prevention of graft-versus-host disease: current perspectives. Therapeutic Advances In Hematology 2023, 14: 20406207231152644. PMID: 36845849, PMCID: PMC9943961, DOI: 10.1177/20406207231152644.Peer-Reviewed Original ResearchHematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantChronic GVHDGVHD prophylaxisDonor hematopoietic stem cell transplantSteroid-refractory chronic GVHDPrevention of graftSevere acute GVHDStem cell transplantAcute GVHDGVHD preventionHLA disparityHost diseaseGraft rejectionHSCT settingUnrelated donorsCalcineurin inhibitorsCell transplantNonmalignant disordersAlternative donorsMouse modelClinical practiceGVHDProphylaxisLimited reports
2022
Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell Disease
Flagg A, Hamidi R, Deng Y, Shah N, Krishnamurti L, He Z. Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell Disease. Blood 2022, 140: 10460-10461. DOI: 10.1182/blood-2022-169107.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply